FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008043257> ?p ?o ?g. }

• W2008043257 endingPage "534" @default.
• W2008043257 startingPage "525" @default.
• W2008043257 abstract "The goal of this study is to evaluate the stability of lyophilized siRNA formulations. The gene silencing efficiency of a stored lyophilized siRNA formulation (i.e. siRNA nanosomes) was evaluated in interferon-α (IFN-α) resistant hepatitis C virus (HCV) at different time points up to three months in an in vitro cell culture model and compared with freshly prepared siRNA formulations. Novel siRNA sequences were encapsulated within nanosize liposomes following condensation with protamine sulfate. The siRNA encapsulated nanosomes were lyophilized and stored at 4 °C for 3 months, along with liquid liposomes (L) and lyophilized liposome powder (P) which were subsequently used to prepare siRNA nanosomes (L) and siRNA nanosomes (P), respectively at different time points. Physiochemical and biological properties of all three formulations were compared at different time points up to 3 months. The particle size of the stored siRNA nanosomes (642 ± 25 nm) was considerably larger initially in comparison with the liquid liposomes (134 ± 5 nm) and lyophilized liposomes (118 ± 3). However, the particle size gradually became smaller over time (413 ± 128 nm by the third month). The zeta potential of all three formulations was initially very high (> +40 mV), followed by a gradual decrease over time. The amount of siRNA in the stored siRNA nanosomes decreased ∼18% during the 3 month storage period (1.16 ± 0.03 nmol initially on day 1 vs. 0.95 ± 0.04 nmol after 3 months). With respect to biological potency, all three formulations were significantly effective to knock-down HCV throughout the storage time. The cell viability was well-maintained throughout this period. Thus, this study indicates that the stored lyophilized siRNA formulation is as effective as the fresh preparation and that long-term storage could be a viable option to treat deadly diseases such as cancer and viral infection." @default.
• W2008043257 created "2016-06-24" @default.
• W2008043257 creator A5006114071 @default.
• W2008043257 creator A5042149364 @default.
• W2008043257 creator A5052237173 @default.
• W2008043257 creator A5075270511 @default.
• W2008043257 creator A5080691070 @default.
• W2008043257 creator A5080971401 @default.
• W2008043257 creator A5081494762 @default.
• W2008043257 date "2012-02-01" @default.
• W2008043257 modified "2023-09-27" @default.
• W2008043257 title "Stability of lyophilized siRNA nanosome formulations" @default.
• W2008043257 cites W1971838403 @default.
• W2008043257 cites W1974769908 @default.
• W2008043257 cites W1992366573 @default.
• W2008043257 cites W1996163490 @default.
• W2008043257 cites W2005501773 @default.
• W2008043257 cites W2006447428 @default.
• W2008043257 cites W2008785883 @default.
• W2008043257 cites W2012547585 @default.
• W2008043257 cites W2016133411 @default.
• W2008043257 cites W2017626786 @default.
• W2008043257 cites W2019003634 @default.
• W2008043257 cites W2025634182 @default.
• W2008043257 cites W2029653860 @default.
• W2008043257 cites W2032775487 @default.
• W2008043257 cites W2033829451 @default.
• W2008043257 cites W2037169692 @default.
• W2008043257 cites W2039109946 @default.
• W2008043257 cites W2041784952 @default.
• W2008043257 cites W2056080501 @default.
• W2008043257 cites W2061812894 @default.
• W2008043257 cites W2077970270 @default.
• W2008043257 cites W2082032640 @default.
• W2008043257 cites W2085603447 @default.
• W2008043257 cites W2087099313 @default.
• W2008043257 cites W2089453395 @default.
• W2008043257 cites W2092244766 @default.
• W2008043257 cites W2112651159 @default.
• W2008043257 cites W2113513945 @default.
• W2008043257 cites W2120621672 @default.
• W2008043257 cites W2127685726 @default.
• W2008043257 cites W2157646788 @default.
• W2008043257 cites W2161051443 @default.
• W2008043257 cites W2168059752 @default.
• W2008043257 cites W273856508 @default.
• W2008043257 cites W3171663738 @default.
• W2008043257 cites W59368335 @default.
• W2008043257 doi "https://doi.org/10.1016/j.ijpharm.2011.11.040" @default.
• W2008043257 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3298087" @default.
• W2008043257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22172291" @default.
• W2008043257 hasPublicationYear "2012" @default.
• W2008043257 type Work @default.
• W2008043257 sameAs 2008043257 @default.
• W2008043257 citedByCount "27" @default.
• W2008043257 countsByYear W20080432572012 @default.
• W2008043257 countsByYear W20080432572013 @default.
• W2008043257 countsByYear W20080432572014 @default.
• W2008043257 countsByYear W20080432572015 @default.
• W2008043257 countsByYear W20080432572016 @default.
• W2008043257 countsByYear W20080432572017 @default.
• W2008043257 countsByYear W20080432572018 @default.
• W2008043257 countsByYear W20080432572019 @default.
• W2008043257 countsByYear W20080432572021 @default.
• W2008043257 crossrefType "journal-article" @default.
• W2008043257 hasAuthorship W2008043257A5006114071 @default.
• W2008043257 hasAuthorship W2008043257A5042149364 @default.
• W2008043257 hasAuthorship W2008043257A5052237173 @default.
• W2008043257 hasAuthorship W2008043257A5075270511 @default.
• W2008043257 hasAuthorship W2008043257A5080691070 @default.
• W2008043257 hasAuthorship W2008043257A5080971401 @default.
• W2008043257 hasAuthorship W2008043257A5081494762 @default.
• W2008043257 hasBestOaLocation W20080432572 @default.
• W2008043257 hasConcept C104317684 @default.
• W2008043257 hasConcept C147789679 @default.
• W2008043257 hasConcept C153911025 @default.
• W2008043257 hasConcept C155672457 @default.
• W2008043257 hasConcept C155887181 @default.
• W2008043257 hasConcept C171250308 @default.
• W2008043257 hasConcept C185154212 @default.
• W2008043257 hasConcept C185592680 @default.
• W2008043257 hasConcept C187530423 @default.
• W2008043257 hasConcept C192562407 @default.
• W2008043257 hasConcept C202751555 @default.
• W2008043257 hasConcept C22615655 @default.
• W2008043257 hasConcept C43617362 @default.
• W2008043257 hasConcept C54009773 @default.
• W2008043257 hasConcept C55493867 @default.
• W2008043257 hasConcept C57992300 @default.
• W2008043257 hasConcept C84199377 @default.
• W2008043257 hasConcept C86181022 @default.
• W2008043257 hasConcept C86803240 @default.
• W2008043257 hasConceptScore W2008043257C104317684 @default.
• W2008043257 hasConceptScore W2008043257C147789679 @default.
• W2008043257 hasConceptScore W2008043257C153911025 @default.
• W2008043257 hasConceptScore W2008043257C155672457 @default.
• W2008043257 hasConceptScore W2008043257C155887181 @default.
• W2008043257 hasConceptScore W2008043257C171250308 @default.

• next